Withdrawal of valproic acid treatment during pregnancy and seizure outcome: Observations from EURAP

SPECCHIO M; PUIJENBROEK E; OTTO NAKKEN K; SCHMITZ B; MARTINEZ M; ZARUBOVA J; KUBA R; MILOVANOVIć M; RUSSELL A; KÄLVIÄINEN R; LUEF G; OHTANI H; SAFCÁK V; TETTENBORN B; KURTHEN M; MAMENISKIENE R; DE MARINIS A; NEUFELD M; ÖZKARA C; KINAY D; ČEBULAR B; KITEVA G, CHI-WAN L; TOMSON T; BATTINO D; BONIZZONI E; CRAIG J; LINDHOUT D; PERUCCA E; SABERS A; THOMAS S; VAJDA F; FINNELL R; ROBERT-GNANSIA E; PANTALEONI C; SCHMIDT B; BRODIE M; MOCHE KAMGA B; GARGANTINI L; PRATO L, CIRILLO S; NARDINI G; ; HSIANG Y; CABRAL L; TOIDZE O; KASRADZE S; VITEZIC D; JEDRZEJCZAK J; KWAN P; BAULAC M; KOCHEN S

Jornada; 2016 International League Against Epilepsy; 2016

Based on data from the EURAP observational International registry of antiepileptic drugs (AEDs) and pregnancy, we assessed changes in seizure control and subsequent AED changes in women who underwent attempts to withdraw valproic acid (VPA) during the first trimester of pregnancy. Applying Bayesian statistics, we compared seizure control in pregnancies where VPA was withdrawn (withdrawal group, n = 93), switched to another AED (switch group, n = 38), or maintained (maintained-therapy group, n = 1,588) during the first trimester. The probability of primarily or secondarily generalized tonic-clonic seizures (GTCS) was lower in the maintained-therapy group compared with the other two groups, both in the first trimester and for the entire duration of pregnancy. GTCS were twice as common during pregnancy in the withdrawal (33%) and switch groups (29%) compared with the maintained-treatment group (16%). Limitations in the data and study design do not allow to establish a cause-effect relationship between treatment changes and seizure outcome, but these observations provide a signal that withdrawal of, or switch from, VPA during the first trimester could lead to loss of seizure control, and highlight the need for a specifically designed prospective observational study.